15 completed, 3 unknown, 1 recruiting. 6 Phase 3, 5 Phase 2, 5 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 5 | Completed 4, Recruiting 1 |
| Phase 4 | 5 | Completed 4, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Peg-IFN: new trials by email Literature Review of Peg-IFN trials Research Report on Peg-IFN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs AHB-137, Peg-IFN, Hepatitis B Vaccine - Chronic Hepatitis B | Phase 2 | Recruiting | Ausper Biopharma Co., Ltd. | 200 | 2025-06-08 | 2026-07-29 |
| The Study on Optimal Treatment and Clinical Outcome of Chronic Hepatitis B Patients With Inactive Hypoviremia PEG-IFN - Chronic Hepatitis B | Unknown | Beijing Ditan Hospital | 1200 | 2022-01-01 | 2022-05-12 | |
| The Study on Clinical Outcome and Treatment Optimization of Chronic Hepatitis B Patients With Hypoviremia PEG-IFN - Chronic Hepatitis B | Unknown | Beijing Ditan Hospital | 1200 | 2022-01-01 | 2022-05-12 | |
| A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B Nucleos(t)ide (NUC), CpAM (RO7049389), TLR7 (RO7020531) - Hepatitis B, Chronic | Phase 2 | Completed | Hoffmann-La Roche | 281 | 2020-07-05 | 2025-09-19 |
| The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg Peginterferon Alfa, Nucleoside Analog (Substance) - Chronic Hepatitis B | Phase 4 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 200 | 2019-01-01 | 2019-01-15 |
| Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C | Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 141 | 2016-06-01 | 2021-03-23 |
| SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection SOF, RBV, Peg-IFN - Hepatitis C | Phase 3 | Completed | Gilead Sciences | 601 | 2013-09-24 | 2017-06-20 |
| Optimized Treatment and Regression of HBV-induced Liver Fibrosis entecavir, Peg-IFN - Liver Fibrosis | Phase 4 | Completed | Beijing Friendship Hospital | 400 | 2013-06-01 | 2018-07-27 |
| Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection LDV/SOF, SOF, RBV - Chronic Hepatitis C | Phase 2 | Completed | Gilead Sciences | 359 | 2013-04-01 | 2018-11-16 |
| A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038) Grazoprevir, pegylated interferon alfa-2b, Ribavirin - Chronic Hepatitis C (CHC) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 87 | 2012-12-07 | 2021-02-04 |
| Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies SOF, RBV, Peg-IFN - Chronic Hepatitis C | Phase 3 | Completed | Gilead Sciences | 534 | 2012-06-01 | 2015-11-09 |
| Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) Vaniprevir, peg-IFN, ribavirin - Hepatitis C, Chronic | Phase 3 | Completed | Merck Sharp & Dohme LLC | 42 | 2011-09-02 | 2018-10-18 |
| Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir Telaprevir, Boceprevir, Peg-IFN - Hepatitis C, Chronic, Cirrhosis | Not applicable | Completed | Louis Stokes VA Medical Center | 50 | 2011-09-01 | 2017-03-15 |
| Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044) vaniprevir, peg-IFN, ribavirin - Hepatitis C, Chronic | Phase 3 | Completed | Merck Sharp & Dohme LLC | 51 | 2011-08-29 | 2018-10-18 |
| Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) vaniprevir, Placebo to vaniprevir, Peg-IFN - Hepatitis C, Chronic | Phase 3 | Completed | Merck Sharp & Dohme LLC | 294 | 2011-06-27 | 2018-10-18 |
| Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B TDF, Peg-IFN - Chronic Hepatitis B | Phase 4 | Completed | Gilead Sciences | 751 | 2011-04-01 | 2016-08-26 |
| Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients alb-interferon alfa 2b, peg-interferon - Chronic Hepatitis C | Phase 2 | Completed | Novartis | 525 | 2008-10-01 | 2016-11-16 |
| Treatment of Acute Hepatitis C Virus in HIV Co-Infection Pegylated interferon alfa-2a + Ribavirin - Hepatitis C, Human Immunodeficiency Virus | Phase 4 | Completed | University of California, San Francisco | 21 | 2008-03-01 | 2020-05-18 |
| Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). HAART, HAART + Immunotherapy - HIV | Phase 4 | Completed | Juan A. Arnaiz | 22 | 2005-03-01 | 2014-11-19 |
Hepatitis C, Chronic (9) · Hepatitis B, Chronic (6) · Hepatitis C (2) · Acquired Immunodeficiency Syndrome (1) · Fibrosis (1) · HIV Infections (1) · Hepatitis B (1) · Liver Cirrhosis (1)
Gilead Sciences (4) · Merck Sharp & Dohme LLC (4) · Beijing Ditan Hospital (2) · Ascletis Pharmaceuticals Co., Ltd. (1) · Ausper Biopharma Co., Ltd. (1) · Beijing Friendship Hospital (1) · Hoffmann-La Roche (1) · Juan A. Arnaiz (1) · Louis Stokes VA Medical Center (1) · Novartis (1) · Third Affiliated Hospital, Sun Yat-Sen University (1) · University of California, San Francisco (1)
China (6) · Canada (5) · Spain (5) · United Kingdom (5) · United States (5) · Australia (4) · France (4) · New Zealand (4) · Germany (3) · Italy (3) · Poland (3) · Taiwan (3) · Greece (2) · Hong Kong (2) · India (2)
Belinda Jump (1) · Bittoo Kanwar, MD (1) · Brad Hare, MD (1) · Hong You, Doctor (1) · Huoling Tang, PhD (1) · Robert H Hyland, DPhil (1) · Yngve Falck-Ytter, MD (1) · Zhiliang Gao (1)
PMID 26947564, PMID 26936417, PMID 22863266, PMID 26143444, PMID 26248087, PMID 26261007, PMID 26353843, PMID 26403160, PMID 26453773, PMID 27367295, PMID 27741230, PMID 27999018, PMID 31608213, PMID 39373164, PMID 39774313, PMID 42456805
2019 (1)